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ABSTRACT
Objective:A study was carried out to compare 3 treatment regimens for vaginal candidiasis.
Methods:A total of 150 women with clinical and mycological evidence ofvaginal candidiasis were
randomized to receive 50 mg of oral fluconazole daily for 6 days (50 women), a single oral 150 mg
dose offluconazole (50 women), or 100 mg ofintravaginal clotrimazole daily for 6 days (50 women).
They were assessed at 5-15 days (short-term assessment) and again at 30-60 days (long-term
assessment) after the completion of treatment.
Results: Candida species were completely eradicated from the vagina in 88% or 80% in the 6-day
oral fluconzaole group, 76% or 70% in the single oral fluconazole group, and 72% or 60% in the
intravaginal clotrimazole group at short-term or long-term assessment, respectively. The rates of
clinical effectiveness were 92% or 88% in the 6-day oral fluconzaole group, 80% or 76% in the single
oral fluconazole group, and 72% or 58% in the intravaginal clotrimazole group at the short-term or
long-term assessment, respectively. Treatment-related side effects were not found in any group.
Conclusions: This study suggests that the treatment ofvaginal candidiasis with oral fluconazole is
effective and that a single oral fluconazole dose might be one choice in the treatment of vaginal
candidiasis. (C) 1995 Wiley-Liss, Inc.
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aginal candidiasis is an infection caused by
Candida albicans or related fungi. The fungi
isolated in the vagina in cases of candidiasis include
C. albicans in 80-90% and others such as C. gla-
brata and C. tropicalis.
The usual transvaginal treatment of candidiasis
can be messy and displeasing and can induce local
irritation, burning, and frequency of micturition.
Consequently, compliance with this form of treat-
ment is poor, as women often stop the treatment as
soon as their symptoms disappear, but prematurely
before eradication of the fungi. Since the rectum is
a carrier of the fungi and relapses are common,
oral ketoconazole is one choice of therapy.
3-s
Fluconazole, a new bis-triazole antifungal agent
which is well absorbed orally with a long systemic
half-life, has the potential for reducing or elimi-
nating episodes of vaginal candidiasis.
6 In animal
models, fluconazole has been shown to be more
potent than ketoconazole against Candida infec-
tions.
7-9
Clotrimazole, which is effective against dermato-
phyte and other fungal infections,
10 has been fre-
quently used for local treatment. This trial was
designed to compare the efficacy oforal fluconazole
with that of intravaginal clotrimazole in the treat-
ment of vaginal candidiasis. The primary criteria
of efficacy were the mycological response and clin-
ical response assessed at 5-15 days and 30-60 days
after the completion of treatment.
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MATERIALS AND METHODS
Study Design
An open, comparative study was conducted in the
Department of Obstetrics and Gynecology, School
ofMedicine, Gifu University, Japan. Patients with
vaginal candidiasis who agreed to participate in this
study were enrolled.
Patients
A total of 150 women with clinical and mycological
evidence of vaginal candidiasis were randomly allo-
cated to receive treatment with 50 mg of oral flu-
conazole daily for 6 days (50 women), a single oral
150 mg dose of fluconazole (50 women), or 100
mg of intravaginal clotrimazole daily for 6 days
(50 women). The clinical diagnosis was initially
based on the presence of pseudohyphae (pseudo-
mycelia) seen in the vaginal discharge with the
light microscope and subsequently confirmed by
culture on Sabouraud chloramphenicol medium
(Nissui Pharmaceutical Co., Ltd., Japan). All pa-
tients were symptomatic with at least vaginal pruri-
tus or burning. Patients with any clinically relevant
associated disease were excluded, as were patients
who were pregnant or lactating or known to have
impaired hepatic or renal function. Women with
venereal disease, chlamydial infection, trichomoni-
asis, or vaginitis other than candidiasis were also
excluded.
Efficacy Assessment
The mycological examination of the vaginal dis-
charge was performed with 2 vaginal swabs: one
was inoculated in a transport medium for Trichomo-
has or bacteria, and the second was transported for
fungal culture on a Sabouraud chloramphenicol
agar (Nissui Pharmaceutical Co., Ltd.) and identi-
fication of the species, after a 48-h incubation, with
an AP120C Auxanogramm (Bio Merieux, France).
C. albicans was distinguished from other species
such as C. tropicalis, C. glabrata, C. parapsilosis,
and C. krusei. For the bacteriological study, a vag-
inal examination was performed and a sample of
vaginal discharge was collected before therapy was
started. Simultaneously, a sample was taken with a
polyester fiber swab (Falcon Applicator, Becton
Dickinson, Cockeysville, MD) and suspended in 5
ml of an anaerobic buffer containing a reducing
agent in a CO2-filled tube. The composition of the
anaerobic buffer was KI--IzPO4:4.0 g; NazHPO4:
6.0 g; L-cysteine HCI" H20:1.0 g; Tween 80
(Sigma Chemical Company, St. Louis, MO): 1.0
g; agar: 1.0 g; and distilled water: 1,000 ml/pH
7.2. All the components were mixed and then heated
at 80C for 30 min to produce a solution. A 9 ml
quantity of the buffer was transferred to a test tube.
Immediately after the air in the tube was replaced
with CO2, the tube was sealed with a butyl rubber
stopper. All tubes and solutions were sterilized in
an autoclave at 115C for 20 min. After the sample
was suspended in the buffer, the tube was resealed
under a continuous stream of carbon dioxide gas of
commercial grade to drive the air out. Exposure of
the sample to atmospheric oxygen was restricted to
no longer than 5 rain. The samples were suspended
in the solution and immediately incubated. For T.
vaginalis, the simple Trichomonas "Fuji" medium
(Fuji Pharmaceutical Co., Ltd., Japan) was used.
The DNA probe method was used for the detection
of chlamydial infection only in cases in which the
macroscopic findings suggested such an infection.
These examinations were undertaken at the base-
line, short-, and long-term assessments. Fungal
eradication was defined as both a negative culture
and negative microscopy for Candida after treat-
ment. Ifother pathogens such as T. vaginalis, Gard-
nerella vaginalis, or Chlamydia species were de-
tected before treatment, the patient was excluded
from the efficacy analysis to assure an accurate eval-
uation of the therapeutic efficacy against candidiasis.
The symptoms and signs of vaginal infection
were recorded before treatment. The significant
parameters for the clinical assessment were subjec-
tive symptoms (genital itching and genital dis-
charge) and objective vaginal findings (state of skin
and genital discharge). The clinical assessment of
effectiveness was made by a doctor and the patient
at 5-15 days (short-term assessment) and again at
30-60 days (long-term assessment) after the last
treatment. The clinical outcome was based upon a
clinical cure (complete disappearance of presenting
signs and symptoms) and symptomatic improve-
ment. Each symptom or sign was assessed by the
same investigator. The statistical analysis was per-
formed by U-test.
Safety Assessment
The side effects were recorded during treatment.
Routine laboratory tests were carried out at the
baseline and short-term assessments.
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TABLE I. Comparison of mycological effectiveness of oral fluconazole and intravaginal clotrimazole in the
treatment of vaginal candidiasis
Clinical effectiveness
(negative fungi) (%)
5th-15th day 30th-60th day
Regimen No. assessment assessment
50 mg of oral fluconazole daily for 6 days
Single oral 150 mg dose of fluconazole
100 mg of intravaginal clotrimazole daily for 6 days
50 88 80
50 76 70
50 72 60
RESULTS
Patients
The mean age of all patients was 32.5 years (range
18-54 years) and the mean body weight was 56.5
kg (range 41.0-77.5 kg). In the 6-day oral flucon-
azole group, the mean age of the patients was 30.4
years (range 20-48 years) and the mean body weight
was 56.5 kg (range 41.0-71.0 kg). In the oral 150
mg fluconazole group, the mean age of the patients
was 35.0 years (range 18-50 years) and the mean
body weight was 56.4 kg (range 43.2-77.5 kg). In
the group receiving 100 mg of intravaginal clotri-
mazole for 6 days, the mean age of the patients was
32.1 years (range 21-54 years) and the mean body
weight was 56.6 kg (range 41.5-69.5 kg).
Efficacy
A comparison of the mycological effectiveness of
oral fluconazole and intravaginal clotrimazole in
the treatment of vaginal candidiasis is shown in
Table 1. Candida species were completely eradi-
cated from the vagina in 88% or 80% in the 6-day
oral fluconazole group, 76% or 70% in the single
oral fluconazole group, and 72% or 60% in the
intravaginal clotrimazole group at the short-term
or long-term assessment, respectively.
A comparison of the clinical effectiveness of oral
fluconazole and intravaginal clotrimazole in the
treatment of vaginal candidiasis is shown in Table
2. The rate of clinical effectiveness was obtained in
92% or 88% in the 6-day oral fluconazole group,
80% or 76% in the single oral fluconazole group,
and 72% or 58% in the intravaginal clotrimazole
group at the short-term or long-term assessment,
respectively. A significant difference was not noted
in the different therapies.
Safety
Neither adverse side effects to the drug nor abnor-
mal laboratory values were noted during the treat-
ment or observation periods.
DISCUSSION
The symptoms of vaginal candidiasis vary from
irritation and discharge in a mild infection to per-
ineal discomfort and dyspareunia in a severe infec-
tion. The long-term cure of vaginal candidiasis is
clinically significant in view of its high recurrence
rate and frequent relapses after conventional topical
therapy. Topical treatment, although effective, is
associated with poor compliance and premature dis-
continuation of the treatment.
11 The relapses asso-
ciated with vaginal fungal infections are also related
to the difficulty of completely eradicating fungi
from the vagina in certain physiological conditions.
Moreover, a single negative culture of the vaginal
lumen does not guarantee that the organisms have
been totally eliminated. Since Candida species in-
vade the tissues, systemic treatment with flucona-
zole could eliminate Candida from the vaginal tis-
sues.
The rectum, an important reservoir of Candida
species, may also be responsible for relapses. In a
previous study on vaginal candidiasis, we detected
C. albican in 35% of women with first-episode
candidiasis and 6% of"women with recurrent can-
didiasis. Since intravaginally administered antifun-
gal agents are minimally absorbed in the body and
are unlikely to influence the rectal flora, the long-
term effectiveness noted with oral fluconazole might
reflect a concomitant reduction of rectal fungal
flora.
In comparing the effectiveness of these 3 regi-
mens of treatment, we found each regimen to be
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TABLE 2. Comparison of clinical effectiveness of oral fluconazole and intravaginal clotrimazole in the treatment
of vaginal candidiasis
Clinical effectiveness
5th-I 5th day Statistical 30th-60th day Statistical
Regimen No. assessment (%) analysis assessment (%) analysis
50 mg of oral fluconazole daily for 6 days 50
Single oral 150 mg dose of fluconazole 50
100 mg of intravaginal clotrimazole daily for 6 days 50
92 N.S. 88 N.S.
80 N.S. 76 N.S.
72 N.S. 58 N.S.
aN.S. not significant.
very effective in the treatment of vaginal candidia-
sis. A significant difference was not noted in the
different therapies, which may be attributable to
the small number of patients or poor statistical
power of this study. However, oral fluconazole
might be more effective in short-term and long-
term assessments, as suggested in previous stud-
ies.
12-16 At the same time, fluconazole, even as a
single oral dose, is effective and reliable in the
treatment of vaginal candidiasis. In addition, the
symptoms of candidiasis are rapidly relieved by
17,18 oral treatment.
In the United States, a comparison ofdrug treat-
ment costs for vaginal candidiasis revealed that the
single dose treatment with fluconazole (150 mg) is
less expensive than intravaginal treatment with clo-
trimazole, miconazole, or terconazole.
19 On the
contrary, in Japan, the national health insurance
(NHI) price of 150 mg of fluconazole is 2,882
yen, while a 6-day course of intravaginal clotrima-
zole, 100 mg daily, costs 477.6 yen. Nevertheless,
cost reductions resulting from decreases in physi-
cian office visits and associated laboratory tests may
result if recurrences and relapses can be reduced
with fluconazole treatment.
The results of our study suggest that the treat-
ment of vaginal candidiasis with oral fluconazole is
effective and that a single oral fluconazole dose
might be one choice in the treatment of vaginal
candidiasis.
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